KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Cash from Investing Activities (2017 - 2025)

Historic Cash from Investing Activities for Elanco Animal Health (ELAN) over the last 9 years, with Q3 2025 value amounting to -$101.0 million.

  • Elanco Animal Health's Cash from Investing Activities fell 10811.9% to -$101.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$305.0 million, marking a year-over-year decrease of 12514.43%. This contributed to the annual value of $1.2 billion for FY2024, which is 78520.71% up from last year.
  • According to the latest figures from Q3 2025, Elanco Animal Health's Cash from Investing Activities is -$101.0 million, which was down 10811.9% from -$56.0 million recorded in Q2 2025.
  • Elanco Animal Health's Cash from Investing Activities' 5-year high stood at $1.2 billion during Q3 2024, with a 5-year trough of -$441.0 million in Q3 2021.
  • Its 5-year average for Cash from Investing Activities is $3.4 million, with a median of -$37.0 million in 2022.
  • In the last 5 years, Elanco Animal Health's Cash from Investing Activities tumbled by 39000.0% in 2022 and then skyrocketed by 355555.56% in 2024.
  • Quarter analysis of 5 years shows Elanco Animal Health's Cash from Investing Activities stood at -$74.0 million in 2021, then dropped by 2.7% to -$76.0 million in 2022, then soared by 53.95% to -$35.0 million in 2023, then plummeted by 157.14% to -$90.0 million in 2024, then fell by 12.22% to -$101.0 million in 2025.
  • Its Cash from Investing Activities stands at -$101.0 million for Q3 2025, versus -$56.0 million for Q2 2025 and -$58.0 million for Q1 2025.